Expression methods to improve the positive rate of CAR-NK cells and application of LDL receptors
By transiently overexpressing LDL receptors on the surface of NK cells and using lentiviral vectors, the gene transduction efficiency of NK cells is improved, the problem of low transduction efficiency of primary NK cells is solved, and efficient preparation of CAR-NK cells is achieved and the improvement of CAR-NK cells is improved. Tumor killing ability.
Patent Information
- Application Number
- CN202211598544.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-14
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-12-14
AI Technical Summary
Primary NK cells are resistant to gene transfection, resulting in low transgene expression, low uptake rate and transduction efficiency of existing vector systems, especially the low infiltration efficiency of lentiviruses on NK cells, affecting the production of CAR-NK cells. and amplification.
By transiently overexpressing LDL receptors on the surface of NK cells, the calcium transfer method, LIPO3000 transfection method and other methods are used to improve the infiltration efficiency of NK cells on lentiviruses. The lentivirus envelope is used as vesicular stomatitis virus glycoprotein G, which includes The CAR gene was transfected.
It significantly improves the positive rate and killing ability of CAR-NK cells, ensures the normal phenotype and function of the cells, and achieves the clinical grade preparation and tumor clearance effect.
Smart Images

Figure CN115960909B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical fields of lentivirus transfection, packaging and the like, and in particular to an LDL receptor gene and an application thereof. Background Art
[0002] Tumor refers to a new growth (neogrowth) formed by the proliferation of local tissue cells under the action of various tumorigenic factors. Because this new growth is mostly a space-occupying mass protrusion, it is also called a neoplasm. Among them, malignant tumors are prone to metastasis, easy to recur after treatment, and extremely difficult to cure under certain special microenvironments.
[0003] Primary NK cells are highly resistant to gene transfection, which results in low uptake rates of NK cells for a variety of vector systems and low transgenic expression of NK cells. Only viral vectors achieve high gene transfer efficiency in primary NK cells. In order to improve the safety of viral vectors, expression systems have been created in which envelope proteins are expressed on separate plasmids. This allows the safe generation of modified viral particles with exogenous envelope proteins in a process called pseudotyping. One way to enhance NK cell transduction is to select the best pseudotype envelope protein. Commonly used vesicular stomatitis virus (VSV) glycoprotein G is usually very effective because it binds to LDL receptors present in a variety of cells. However, it has low infection efficiency for lymphocytes, and because the expression of LDL receptors on the surface of NK cells is extremely low, even with high virus titer infiltration, it cannot effectively improve the infiltration efficiency and is often toxic to cells.
[0004] In recent years, tumor immunotherapy has developed rapidly, especially adoptive cell therapy (ACT), which refers to the method of isolating immune cells such as T cells and NK cells from the patient's body, modifying and amplifying them in vitro, and then returning them to the patient's body for tumor treatment. In 2013, tumor immunotherapy was rated as the first of the "Top Ten Breakthroughs" by Science magazine.
[0005] CAR-T and TCR-T are important components of adoptive cell therapy, especially CAR-T therapy, which has made remarkable achievements in the treatment of hematological tumors and achieved a high remission rate. The typical CAR structure consists of three parts: scFv for extracellular recognition of tumor antigens, hinge and transmembrane domains, intracellular co-stimulatory signals and activation domains. The first generation of CAR does not contain intracellular co-stimulatory signals, and the killing activity of CAR-T cells is low and the survival time is short. Therefore, the second generation of CAR began to add co-stimulatory signals such as CD28 and 4-1BB. The characteristics of CAR-T cells using different co-stimulatory signals are also different. CD28 enhances the killing activity of CAR-T cells, while 4-1BB enhances the killing activity of CAR-T cells and prolongs the survival time of CAR-T cells. Subsequently, the third generation of CAR that co-expresses two co-stimulatory signal domains appeared, but its anti-tumor effect is not as good as the second generation of CAR-T. Therefore, the current clinical application is mainly the second generation of CAR-T cells.
[0006] NK cells with CAR receptors (CAR-NK) are considered an effective anti-cancer tool. Initially, the creation of CAR-NK cells was performed using structures developed for CAR-T cells; however, recent developments have incorporated adaptations for NK cells. However, NK cells pose special and unique problems. Unlike T cells and B cells, NK cells do not typically expand clonally, which makes the generation, maintenance, and expansion of CAR-NK cells challenging. The most important stages in the generation of NK-CAR cells are the introduction of genetic elements into the NK cells themselves and the subsequent expansion of CAR-NK cells. Summary of the invention
[0007] Based on the above problems, the problem to be solved by the present invention is to provide an LDL receptor gene that can transiently overexpress LDL receptor on the surface of NK cells and effectively improve the efficiency of lentivirus infection.
[0008] The technical solution of the present invention is as follows:
[0009] An expression method for improving the positive rate of CAR-NK cells comprises the following steps:
[0010] NK cells are activated and transiently overexpress LDL receptors;
[0011] NK cells overexpressing LDL receptor were infected with lentivirus.
[0012] NK cells are activated and transiently overexpress LDL receptors, and LDL receptors are transiently overexpressed on the surface of activated NK cells by transient transfection, and the transient transfection method includes any one of calcium transfection method, LIPO3000 transfection method, liposome transfection method and other kit transfection methods.
[0013] NK cells overexpressing LDL receptors are infected with lentivirus, and the CAR gene is expressed in the treated NK cells by lentivirus infection. The NK cell activation method includes antibody activation, magnetic bead activation, cell stimulation, chemical reagents and other kit activation methods. One or more combinations; the lentivirus envelope is vesicular stomatitis virus glycoprotein G (VSV-G), and the lentivirus contains the CAR gene. The lentivirus packaging process includes any one of the three-plasmid system and the four-plasmid system.
[0014] In one embodiment, in the expression method, the step of activating NK cells and transiently overexpressing LDL receptors further comprises the following steps:
[0015] NK cells were obtained from peripheral blood and cultured at 5.0 × 10 5 The cells were inoculated into a 24-well plate at a density of 10 cells / well, and culture medium was added to the 24-well plate for NK cell culture;
[0016] After culturing NK cells for 16–18 h, the medium was removed and replaced with serum-free medium for 1 h;
[0017] The plasmid transfection mixture was added into a 24-well plate to perform transient transfection on NK cells;
[0018] Six hours after transfection, the mixed solution in the 24-well plate was removed and replaced with complete culture medium; 48 hours after transfection, the supernatant NK cell suspension was collected, at which time the NK cells were activated and transiently overexpressed LDL receptors.
[0019] In one embodiment, in the expression method, when NK cells are cultured without serum, every 5.0×10 5 Add 200-500 μl serum-free medium per cell.
[0020] In one embodiment, in the expression method, the plasmid transfection mixture includes four plasmids, Lipo 3000 and OPTI-MEM, and the ratio of Lipo 3000 to the total number of four plasmids is 2:1 (v / m), and the amount of OPTI-MEM is 100-300ul.
[0021] In one embodiment, in the expression method, the step of infecting the NK cells overexpressing LDL receptor with a lentivirus further comprises the following steps:
[0022] Adding a transfection aid to the activated NK cell suspension transiently overexpressing LDL receptor to obtain a NK cell transfection suspension;
[0023] Add lentivirus to the NK cell transfection suspension to perform lentivirus transfection;
[0024] After the lentiviral transfection is completed, complete culture medium is added to culture the lentiviral-transfected NK cells; the cell suspension is then collected for later use.
[0025] In one embodiment, in the expression method, the transfection aid is Polybrene or serum-free medium containing basic amino acids; and 2 μl to 20 μl of the transfection aid is added to every 1 ml of NK cell suspension.
[0026] In one embodiment, in the expression method, in the lentivirus transfection step, the amount of lentivirus added is MOI=1-20, and the transfection time is 6-24 hours.
[0027] In one embodiment, in the expression method, when culturing NK cells after lentivirus transfection, the amount of complete medium added should maintain the cell concentration at 5.0×10 5 cells / ml.
[0028] In one embodiment, in the expression method, the complete culture medium is a complete culture medium containing 10-20% v / v FBS.
[0029] The above-mentioned CAR genes include second-generation, third-generation, fourth-generation and fifth-generation CARs; the CAR structural targeting targets include any one or more of CLDN18.2, GUCY2C, Nectin4, GPC3, CD19 and CD22.
[0030] In the above expression method, the nucleic acid sequence of the LDL receptor gene is shown in SEQ ID NO: 1; the LDL receptor gene can increase the positive rate of CAR-NK cells.
[0031] A vector comprising an LDL receptor gene; preferably, the vector comprises a plasmid, DNA or mRNA.
[0032] An expression cassette comprising an LDL receptor gene, or comprising the above-mentioned vector.
[0033] A recombinant microorganism comprising an LDL receptor gene, the above-mentioned vector or the above-mentioned expression cassette
[0034] A recombinant NK immune cell, comprising an LDL receptor gene, the above-mentioned vector or the above-mentioned expression box.
[0035] In one embodiment, in the recombinant NK immune cell structure, a CMV or EF1a promoter is provided before the LDL receptor gene, and an eGFP fluorescent gene is provided after the LDL receptor gene; wherein the LDL receptor gene and the eGFP gene are separated by a protein segmentation element, and the protein segmentation element includes any one of T2A, P2A, E2A, F2A and IRES.
[0036] In one embodiment, in the CAR-NK cells, the plasmid expression cassette includes one or more of an LDL receptor overexpression gene expression cassette, a lentiviral envelope gene expression cassette, and a CAR gene expression cassette.
[0037] A biological preparation, comprising an LDL receptor gene, the above-mentioned vector, the above-mentioned expression cassette, or the above-mentioned recombinant immune cell; and the biological preparation can be used to prepare a drug for treating / preventing tumors and / or cancer.
[0038] Compared with the prior art, the present invention has the following beneficial effects:
[0039] 1. Transient overexpression of LDL receptors on the surface of NK cells does not affect the normal phenotype and development process of NK cells;
[0040] 2. Effectively improve the infection efficiency of NK cells and solve the problem of low efficiency of NK cell lentivirus infection;
[0041] 3. The infected CAR-NK cells maintain good killing ability and can reach clinical standards after process optimization.
[0042] The CAR-NK cell preparation method provided by the present invention can safely, conveniently and effectively prepare clinical-grade CAR-NK cells, and ensure that they have a very high positive rate and preparation success rate. Through process optimization, it is ensured that its various detection indicators meet clinical needs, and its proper functions and phenotypes are fully retained, with a very high tumor clearance effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 The diagrams are the protein and amino acid sequence structure design diagrams in CAR-NK immune cells; A# is the LDLR protein structure, using the P2A protein cutting element to split the LDLR protein and the eGFP fluorescent marker protein; B# is the CAR structure design diagram;
[0044] Figure 2 The phenotypic flow cytometry results of target cells HGC-27 and HGC27-CLDN18.2;
[0045] Figure 3a , 3b They are the results of phenotype detection of NK cells isolated and purified from PBMC; Figure 3a NK cells blank control, Figure 3b This is the result of NK cell CD3 / CD56 phenotype detection;
[0046] Figure 4a , 4bThey are respectively the detection diagrams of NK cell transiently transfected with LDLR expression; among them, 4a is the NK cell blank control, and 4b is the positive expression detection result after NK cell transiently transfected with LDLR;
[0047] Figure 5a , 5b They are the CAR positive rate detection diagrams of CAR-NK and CAR-LDLR-NK cells respectively; among them, Figure 5a This is the CAR positive rate test result of CAR-NK cells; Figure 5b This is the CAR positive rate test result of CAR-LDLR-NK cells;
[0048] Figure 6 It is the expansion growth curve of CAR-NK and CAR-LDLR-NK cells;
[0049] Figure 7a , 7b These are the in vitro killing effects of CAR-NK and CAR-LDLR-NK cells on tumor cells; Figure 7a The target cell is HGC27; Figure 7b The target cells are HGC27-CLDN18.2;
[0050] Figure 8 This is the survival curve of CAR-NK and CAR-LDLR-NK cell animal experiments. DETAILED DESCRIPTION
[0051] The preferred embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings.
[0052] Design principle of the present invention:
[0053] Primary NK cells are highly resistant to gene transfection, which results in low uptake rates of NK cells for a variety of vector systems and low transgenic expression of NK cells. Only viral vectors achieve high gene transfer efficiency in primary NK cells. In order to improve the safety of viral vectors, expression systems have been created in which envelope proteins are expressed on separate plasmids. This allows the safe generation of modified viral particles with exogenous envelope proteins in a process called pseudotyping. One way to enhance NK cell transduction is to select the best pseudotype envelope protein. Commonly used vesicular stomatitis virus (VSV) glycoprotein G is usually very effective because it binds to LDL receptors present in a variety of cells. However, it has low infection efficiency for lymphocytes, and because the expression of LDL receptors on the surface of NK cells is extremely low, even with high virus titer infiltration, it cannot effectively improve the infiltration efficiency and is often toxic to cells. Therefore, the present invention pioneered the method of overexpressing LDL receptors on the surface of NK cells by transient transfection before the lentivirus infects NK cells, thereby greatly improving the infection efficiency of the lentivirus carrying the VSV-G envelope protein. This design takes into account the improvement of the lentivirus infection effect and the stabilization of the genotype and phenotype of NK cells to the greatest extent. The CAR-LDLR-NK cell killing effect of the present invention is accurate, safe, and not prone to recurrence, which can effectively improve the quality of life of patients.
[0054] The method for preparing the above-mentioned CAR-LDLR-NK cells is to transiently overexpress the LDL receptor on the surface of activated NK cells by transient transfection, and then express the CAR gene in the treated NK cells by lentiviral infection.
[0055] In the present invention, the LDL receptor gene expression vector in the preparation method includes plasmid, DNA and mRNA.
[0056] The LDL receptor gene provided by the present invention can improve the positive rate of CAR-NK cells, and its nucleic acid sequence is shown in SEQ ID NO: 1, and the amino acid sequence of the LDL receptor gene is shown in SEQ ID NO: 2; wherein:
[0057] The nucleic acid sequence is shown in SEQ ID NO: 1:
[0058]
[0059] The amino acid sequence is as shown in SEQ ID NO:2:
[0060] MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA。
[0061] In the present invention, a promoter including CMV, EF1a, etc. is provided before the LDL receptor gene, and an eGFP fluorescent gene is added after the LDL receptor gene. The LDL receptor gene and the eGFP gene are separated by a protein segmentation element, and the protein segmentation element includes any one of T2A, P2A, E2A, F2A and IRES.
[0062] In the present invention, NK cells are obtained by culturing peripheral blood, i.e., umbilical cord blood NK cells. This part belongs to the prior art and can be obtained by conventional processes; it will not be described in detail here.
[0063] In the present invention, the expression method for improving the positive rate of CAR-NK cells has the following preparation process:
[0064] First, NK cells are activated and transiently overexpress LDL receptors;
[0065] Then, the LDL receptor is infected with the lentiviral envelope.
[0066] In the present invention, the transient transfection method includes any one of calcium transfection method, Lipo3000 transfection method, liposome transfection method and other kit transfection methods.
[0067] In the present invention, the NK cell activation method includes any one or more combinations of antibody activation method, magnetic bead activation method, cell stimulation method, chemical reagent method and other kit activation methods.
[0068] NK cells were activated and transiently overexpressed with LDL receptors before lentiviral infection.
[0069] The step of activating NK cells and transiently overexpressing LDL receptors further includes the following steps:
[0070] NK cells were obtained from peripheral blood and cultured at 5.0 × 10 5 The cells were inoculated into a 24-well plate at a density of 10 cells / well, and culture medium was added to the 24-well plate for NK cell culture;
[0071] After culturing NK cells for 16-18 hours, the medium was removed and replaced with serum-free medium for 1 hour; 5 Add 200-500 μl serum-free medium to each cell.
[0072] The plasmid transfection mixture was added into a 24-well plate to perform transient transfection on NK cells;
[0073] 6 hours after transfection, the mixed solution in the 24-well plate was removed and replaced with complete culture medium; 48 hours after transfection, the supernatant NK cell suspension was collected, at which time the NK cells were activated and transiently overexpressed LDL receptors; wherein, the complete culture medium was a complete culture medium containing 10~20% v / v FBS.
[0074] In the present invention, the lentivirus envelope is vesicular stomatitis virus glycoprotein G (VSV-G), and the lentivirus contains a CAR gene; the lentivirus packaging process includes any one of a three-plasmid system and a four-plasmid system; wherein the plasmid transfection mixture includes four plasmids, Lipo3000 and OPTI-MEM, and the total amount of Lipo3000 and four plasmids is 2:1 (v / m), and OPTI-MEM is 100~300ul.
[0075] In the present invention, CAR genes include second-generation, third-generation, fourth-generation, and fifth-generation CARs. CAR structural targeting targets include any one or more of CLDN18.2, GUCY2C, Nectin4, GPC3, CD19, and CD22.
[0076] In the expression method for improving the positive rate of CAR-NK cells, the step of performing lentiviral infection on NK cells overexpressing LDL receptors also includes the following steps:
[0077] Adding a transfection aid to the activated NK cell suspension transiently overexpressing LDL receptor to obtain a NK cell transfection suspension;
[0078] Adding lentivirus to the NK cell transfection suspension to perform lentivirus transfection; wherein the amount of lentivirus added is MOI=1-20, and the transfection time is 6-24 hours;
[0079] After the lentiviral transfection is completed, complete culture medium is added to culture the lentiviral transfected NK cells; the cell suspension is then collected for later use; the amount of complete culture medium added should maintain the cell concentration at 5.0×10 5 The total amount of culture medium is 10-20% v / v FBS.
[0080] Wherein, the transfection aid is a Polybrene aid or a serum-free medium containing basic amino acids; and 2 μl to 20 μl of the transfection aid is added to each 1 ml of NK cell suspension. In the present invention, it is preferred that the transfection aid is a serum-free medium containing basic amino acids, and the basic amino acids include 1 mg / ml to 50 mg / ml histidine, 1 mg / ml to 50 mg / ml lysine, and 1 mg / ml to 50 mg / ml arginine, and the serum-free medium is any one of DMEM, IMEM, RPMI-1640, KPM-581, and OPTMIZER TCELLEXPANSFMCTS.
[0081] In the present invention, the lentivirus is a plasmid transfer vector.
[0082] In the present invention, the expression cassette of the plasmid includes one or more of the above-mentioned LDL receptor overexpression gene expression cassette, lentiviral envelope gene expression cassette, CAR gene expression cassette, etc.
[0083] In the present invention, the recombinant microorganism contains any of the above-mentioned LDL receptor genes, or contains the above-mentioned expression cassette, or the above-mentioned vector.
[0084] In the present invention, the immune cell is a recombinant NK immune cell, which includes the above-mentioned LDL receptor gene, or the above-mentioned expression cassette, or the above-mentioned vector.
[0085] In the present invention, the biological preparation includes the above-mentioned LDL receptor gene, or the above-mentioned expression cassette, or the above-mentioned vector, or the above-mentioned recombinant NK immune cell.
[0086] In the present invention, the biological preparation can be used in the preparation of drugs for treating / preventing tumors and / or cancers; in addition, the CAR-LDLR-NK cells prepared by the above method can also be made into a biological preparation, which is a pharmaceutically acceptable carrier, diluent or excipient.
[0087] Administration of the biologic may be carried out in any convenient manner, including by nebulization, injection, swallowing, infusion, implantation or transplantation. The biologic may be used in medicine for the prevention and / or treatment of solid tumors.
[0088] The CAR-LDLR-NK cells provided by the present invention solve the problem of low CAR positivity rate in traditional lentiviral infection methods, greatly improve the efficiency of lentiviral infection, and maintain good tumor killing ability and effectiveness and safety of immune cell therapy.
[0089] The following examples use the preparation of CAR-LDLR-NK cells from peripheral blood as an example to describe in detail the preparation method and functional verification of immune cells.
[0090] The method for preparing immune cells specifically includes the following contents:
[0091] 1. Protein structure design;
[0092] 2. Construct CAR-LDLR-NK cells overexpressing LDLR and conduct in vitro functional tests;
[0093] 3. In vivo functional test of CAR-LDLR-NK cells.
[0094] Example 1. Protein structure design and target cell line culture
[0095] 1. Protein structure design
[0096] according to Figure 1 As shown in the structural diagram, design A# is the LDLR (i.e. LDL) protein structure, and the T2A protein cutting element is used to separate the LDLR protein and the eGFP fluorescent marker protein; B# is the CAR structure design diagram, and the target protein binding domain of the CAR structure is anti-CLDN18.2 scFv, and other structures include signal peptide CD8SP, transmembrane domain CD8Hinge, CD8TM, intracellular activation element 4-1BB and CD3Zeta.
[0097] 2. Lentivirus preparation and target cell line culture
[0098] The CLDN18.2 expression base sequence was cloned into the PHBLV lentiviral vector backbone and placed under the promoter of EF1α (EF-1α) to form PHBLV-EF1α-CLDN18.2. The three plasmids, including PHBLV-EF1α-CLDN18.2, lentiviral envelope plasmid pMD2.G (Addgene, Plasmid #12259) and lentiviral packaging plasmid psPAX2 (Addgene Plasmid #12260), were transferred into the complete lentiviral expression vector prepared in 293T cells using Lipo3000; then the viral supernatant was collected at 48h and 72h, respectively, and the collected viral supernatant was concentrated by ultracentrifugation (Merck Millipore); the concentrated virus can be used to infect HGC-27, and finally the HGC-27 cell line overexpressing CLDN18.2 was obtained, named HGC-27-CLDN18.2.
[0099] like Figure 2As shown in FIG. 1 , the detection results of HGC-27-CLDN18.2 cells expressing CLDN18.2; wherein, HGC-27 cells are negative control cells that do not overexpress CLDN18.2, and the corresponding detection graph is a negative control graph; according to the detection results corresponding to HGC-27-CLDN18.2 and HGC-27, Figure 2 As can be seen from the two vertical figures, the results of detecting the CLDN18.2 antigen expression level in the FITC channel showed that CLDN18.2 expression in HGC-27 was negative (the peak graph was located on the left side of the vertical line), and CLDN18.2 expression in HGC-27-CLDN18.2 was positive (the peak graph was located on the right side of the vertical line).
[0100] Example 2: Isolation of peripheral blood PBMC and NK cells
[0101] Mononuclear cells were isolated from the donor's peripheral blood, density gradient centrifugation was performed using the ficol method, and NK cells were enriched using a NK cell sorting kit. The sorting and enrichment kits are commercial product technologies and will not be described in detail here.
[0102] When NK cells were cultured, TexMACS GMP Medium (Miltenyi Biotec, 170-076-309) was used. The culture medium contained 10% FBS, 2mM L-glutamine and 100IU / ml rhIL-2. The cells were cultured in a constant temperature incubator at 37°C and 5% CO2. The culture cycle was 13 days, and the cells were cultured statically. During this period, the cells were replenished every 2 days or so, and the amount of replenishment was determined according to the number of cells.
[0103] NK cell phenotype was double-stained with CD3 / CD56 flow cytometry antibodies. The test results are as follows: Figure 3a , 3b As shown. Figure 3a Unstained NK cells were used as negative control. Figure 3b This is the result of CD3 / CD56 double antibody staining of NK cells, among which CD3- / CD56+ phenotype cells account for 91.3% of NK cells.
[0104] Example 3: Transient expression of LDLR in NK cells
[0105] NK cells were counted and cell viability, density and number were recorded; the number of cells inoculated in a 24-well plate was 5.0×10 5 cells / well, add 2 ml of complete medium containing 12% v / v FBS, and culture statically;
[0106] After 16 to 18 h of static culture, discard the old complete medium and replace it with 1 ml of serum-free medium and incubate for 1 h;
[0107] Find two separate tubes, marked as tube A and tube B. Tube A includes: 125 μl opti-MEM, 5 μl Lipo3000; tube B includes: 125 μl opti-MEM, 2.5 μg plasmid. Then mix tube A and tube B to prepare a plasmid transfection mixture and incubate for 15 minutes. Then, add the plasmid transfection mixture evenly into a 24-well plate and perform transient transfection on NK cells. After 6 hours of transfection, discard the transfection mixture and replace it with 2 ml of complete culture medium. After 48 hours of transfection, collect the supernatant NK cell suspension. At this time, the NK cells are activated and transiently overexpress LDL receptors.
[0108] The expression of target protein was detected by flow cytometry. Figure 4a , 4b As shown, Figure 4a NK cells blank control, Figure 4b The positive rate of NK cells transiently transfected with LDLR was 80.53%, and the transiently transfected NK cells were named NK-LDLR.
[0109] The positive control CLDN18.2-CAR was packaged with lentivirus, and the CAR-NK and CAR-LDLR-NK were prepared by lentivirus infection of NK and NK-LDLR cells at MOI=3. The positive rate test results of the obtained CAR-NK and CAR-LDLR-NK cells are as follows: Figure 5a , 5b As shown, Figure 5a For the CAR-NK control sample, the positive rate test result was 11.55%; Figure 5b The results of the positive rate test of CAR-LDLR-NK cells after lentivirus infection of NK-LDLR cells showed that the positive rate of CAR-LDLR-NK cells was 80.3%, which was 7 times higher than that of ordinary NK cells.
[0110] Example 4: Lentivirus transfection
[0111] According to the concentration of amino acids in the solution, the following components are provided: 50 mg / ml histidine, 10 mg / ml lysine, 10 mg / ml arginine and the remainder OPTMIZER TCELL EXPANSFMCTS serum-free medium, and the transfection aid is prepared by mixing;
[0112] Adding a transfection aid to the NK cells activated and transiently overexpressing LDL receptor obtained in Example 3 to obtain a NK cell transfection suspension;
[0113] Add lentivirus with MOI=5 to the NK cell transfection suspension and perform lentivirus transfection for 12 hours;
[0114] After lentiviral transfection, complete medium containing 18% v / v FBS was added to maintain the cell concentration at 5.0 × 10 5 cells / ml, and then cultured the NK cells after lentivirus transfection normally; then collected the cell suspension and performed flow cytometry to detect the positive detection of CAR.
[0115] The proliferation of cells after lentivirus infection was detected. The proliferation of NK cells was as follows Figure 6 As shown, CAR-NK and CAR-LDLR-NK cells showed basically the same expansion capacity, indicating that the transient transfection process had no effect on the proliferation state of NK cells.
[0116] Example 5: Evaluation of cell killing experiments
[0117] 1. Evaluation of cell killing assay in vitro
[0118] HGC-27 and HGC-27-CLDN18.2 cells were used as negative and positive target cells, respectively, and flow cytometry was used to verify the in vitro tumoricidal function of CAR-NK and CAR-LDLR-NK cells.
[0119] like Figure 7a , 7b As shown, Figure 7a The target cell is HGC27; Figure 7b The target cells are HGC27-CLDN18.2.
[0120] Figure 7a The test results showed that CAR-NK and CAR-LDLR-NK had no killing effect on HGC-27; Figure 7b The test results showed that CAR-NK and CAR-LDLR-NK showed specific killing effects on HGC-27-CLDN18.2 cells that expressed positively for CLDN18.2; in contrast, the specific killing efficiency of CAR-LDLR-NK cells on HGC-27-CLDN18.2 cells was slightly higher than that of general CAR-NK cells.
[0121] 2. In vivo cell killing experiment
[0122] 42 6-8 week old NSG mice (weight 18-22 g) were selected and acclimated for one week before being subcutaneously inoculated with HGC-27-CLDN18.2 tumor cell line. Each mouse was inoculated with 5×10 6 The animal status was closely observed and the tumor volume of the mouse was measured with a vernier caliper every three days. When the tumor volume reached 100 mm 3The mice were randomly divided into groups according to their weight and tumor size, and CAR-T cells or control T cells were infused through the tail vein. The detailed administration method, dosage and route of administration are shown in Table 1. One week after the completion of administration, before the tumor completely disappeared, one mouse was randomly selected from the group and killed, and tumor tissue was collected to detect the tumor infiltration of CAR-T. This mouse was not included in the survival curve statistics.
[0123]
[0124] like Figure 8 As shown, CAR-NK and CAR-LDLR-NK can significantly prolong the survival of mice compared with the NK cell and DPBS groups, and the survival of the CAR-LDLR-NK group is slightly longer than that of the CAR-NK group. There is no significant difference in the survival of the two groups, which proves that the transient transfection process has no effect on the long-term tumor killing effect of NK cells.
[0125] The above examples prove that the process of transiently overexpressing LDLR in NK cells can effectively improve the transduction efficiency of CAR gene by lentivirus, and can prepare CAR-LDLR-NK cells with a CAR positivity rate far exceeding that of general processes, and has no significant effect on the phenotype, proliferation ability and in vivo and in vitro tumoricidal activity of CAR-NK cells compared with general processes, and effectively improves the survival time of mice. When NK cells with the same CAR positivity rate are required, the total number of cells required for high CAR positivity rate is less, which is equivalent to reducing the cost of cell culture in disguise.
[0126] It should be understood that the above description of the preferred embodiments of the present invention is relatively detailed and cannot be regarded as limiting the scope of patent protection of the present invention. The scope of patent protection of the present invention shall be based on the attached claims.
Claims
1. An expression method for increasing the positive rate of CAR-NK cells, It is characterized in that The steps include: NK cells are activated and transiently overexpress LDL receptors; the nucleic acid sequence of the LDL receptor gene is shown in SEQ ID NO: 1; NK cells overexpressing LDL receptors were infected with lentivirus, and the CAR gene was expressed in the treated NK cells by lentivirus infection; Among them, the CAR gene structure includes signal peptide CD8SP, target protein binding domain CLDN18.2 scFv, transmembrane domain CD8Hinge, CD8TM, intracellular activation element 4-1BB and CD3Zeta.
2. The expression method according to claim 1, It is characterized in that The step of activating NK cells and transiently overexpressing LDL receptors further includes the following steps: NK cells were obtained from peripheral blood and cultured at 5.0 × 10 5 The cells were inoculated into a 24-well plate at a density of 10 cells / well, and culture medium was added to the 24-well plate for NK cell culture; After culturing NK cells for 16–18 h, the medium was removed and replaced with serum-free medium for 1 h; The plasmid transfection mixture was added into a 24-well plate to perform transient transfection on NK cells; Six hours after transfection, the mixed solution in the 24-well plate was removed and replaced with complete culture medium; 48 hours after transfection, the supernatant NK cell suspension was collected, at which time the NK cells were activated and transiently overexpressed LDL receptors.
3. The expression method according to claim 2, It is characterized in that When NK cells were cultured in serum-free culture, 5.0×10 5 Add 200-500 μl serum-free medium per cell.
4. The expression method according to claim 2, It is characterized in that The plasmid transfection mixture includes four plasmids, Lipo 3000 and OPTI-MEM, and the total amount of Lipo 3000 and four plasmids is 2:1 v / m, and OPTI-MEM is 100-300ul.
5. The expression method according to claim 1, It is characterized in that The step of infecting the NK cells overexpressing LDL receptors with lentivirus also includes the following steps: Adding a transfection aid to the activated NK cell suspension transiently overexpressing LDL receptor to obtain a NK cell transfection suspension; Add lentivirus to the NK cell transfection suspension to perform lentivirus transfection; After the lentiviral transfection is completed, complete culture medium is added to culture the lentiviral-transfected NK cells; the cell suspension is then collected for later use.
6. The expression method according to claim 5, It is characterized in that The transfection aid is a Polybrene aid or a serum-free culture medium containing basic amino acids; and 2 μl to 20 μl of the transfection aid is added to every 1 ml of NK cell suspension.
7. The expression method according to claim 5, It is characterized in that In the lentivirus transfection step, the amount of lentivirus added is MOI=1-20, and the transfection time is 6-24 hours.
8. The expression method according to claim 5, It is characterized in that When culturing NK cells after lentiviral transfection, the amount of complete medium added should maintain the cell concentration at 5.0×10 5 cells / ml.
9. The expression method according to claim 2 or 5, It is characterized in that The complete culture medium is a complete culture medium containing 10-20% v / v FBS.
